Press Releases

JP Morgan Health Care Conference banner
Atomwise Invited to Present at the 2022 J.P. Morgan Healthcare Conference

Leading AI-pharma company among select few private companies to participate San Francisco, CA – January 5, 2022 – Atomwise, a technology-enabled pharmaceutical company leveraging the power of artificial intelligence (AI) to revolutionize small molecule drug discovery, today announced that it has been invited to present next week at the 40th Annual J.P. Morgan Healthcare Conference. […]


January 5, 2022
Atomwise and OncoStatyx announce Joint Venture to develop small molecule inhibitors of oncology target KDM5B

Atomwise and OncoStatyx announce a joint venture to discover and develop small molecule compounds that inhibit KDM5B.


September 10, 2019
SEngine Precision Medicine and Atomwise Announce Strategic Joint Venture to Accelerate Novel Drug Discovery

Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients SEATTLE, Wash., and SAN FRANCISCO, Calif. – SEngine Precision Medicine and Atomwise, Inc. today announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development. […]

Research collaboration between U-M and Atomwise to accelerate drug discovery using innovative Artificial Intelligence approach

Ann Arbor, Michigan – From making pain management safer and more effective to identifying inhibitors for a fibrosis target protein and more, researchers from Michigan Medicine, as well as the University of Michigan College of Pharmacy and U-M Life Sciences Institute, are looking to advance their projects through Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards […]

Atomwise and Enamine to Advance Pediatric Oncology with the World’s First and Largest Ten Billion Compound Virtual Screen

Atomwise, Enamine, and top university researchers collaborate to discover novel small molecules for the treatment of pediatric cancers using the power of AI and novel chemistry. SAN FRANCISCO, Calif., and KIEV, Ukraine, June 24, 2019 – Atomwise, Inc. today announced the launch of a 10 billion compound AI-powered virtual drug screening initiative, the 10-to-the-10 program, […]


June 23, 2019
Atomwise Announces Multi-year, Multi-target Agreement with Lilly for AI-Driven Drug Discovery Program

Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential […]

DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases

Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development   GENEVA, Switzerland and SAN FRANCISCO, USA (April 16, 2019) – Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected […]